Raltegravir Activity In Lymphoid Tissues

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The reduction with antiretroviral therapy (ART) of HIV RNA in blood, and HIV RNA in infected cells and in viruses associated with the follicular dendritic cell (FDC) network in lymphatic tissues, typically follows a two-phase pattern of decline. The half-life of the first-phase is about 1 day and that of the second phase is about 14 days, with comparable estimates for first-phase decay in SIV-infected rhesus macaques.

While substantial evidence supports the current view that first-phase decay reflects the death of activated CD4+ T cells infected before ART was begun, the sources of viral RNA in the second phase have not as yet been conclusively established. Possible sources of viral RNA that have been invoked in mathematical models, or for which there is experimental evidence, include longer-lived infected cells such as macrophages and resting CD4+ T cells, dissociation of virus from the FDC network, and productively infected CD4+ T cells that are not subject to clearance by host immune responses because of waning levels of HIV antigen.

Raltegravir (MK-0518) belongs to a new class of integrase inhibitors that potently suppress HIV and SIV replication, and reportedly markedly alters the second phase HIV decline in a way that challenges the current view that longer-lived infected cells are the source of virus in this phase. While mathematical modeling of decay of HIV RNA in blood was most consistent with 1) cells newly infected by long-lived cells, or 2) from activation of latently infected cells with full-length unintegrated HIV DNA as a source of second phase virus, we think the data are also quite consistent with the greater efficacy of integrase inhibitors in a particular cell type and/or anatomic site such as the gut.

In this protocol we will test the hypothesis that the rapid decrease in HIV replication associated with raltegravir is due to a more complete suppression of viral replication in lymphatic compartments such as lymph nodes and gastrointestinal lymphatic tissue. We will also investigate compartment-specific intracellular levels of raltegravir to potentially explain differences in changes in these compartments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

NCT00781287

Human Immunodeficiency Virus

TERMINATED PHASE4

The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection

NCT00641641

HIV Infection

COMPLETED NA

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy

NCT00709397

HIV-1 Infection

TERMINATED

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

NCT00660972

HIV Infections

COMPLETED PHASE1

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women

NCT00984152

HIV-1 Infections

WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will evaluate rates of HIV elimination in peripheral blood in comparison to secondary lymphatic tissues, including inguinal lymph nodes (LN) and gastrointestinal lymphatic tissues (GALT). HIV-infected patients who are antiretroviral therapy (ART) naive and fit criteria to initiate ART will be randomized to either Truvada (tenofovir/emtricitabine) + Sustiva (efavirenz - 600mg qDAY orally - standard of care) or Truvada + Isentress (raltegravir - 400mg BID orally).

Patients will have a blood draw, a colonoscopy with biopsies, and inguinal lymph node excision at days 0, 2, 7, 14, and week 52. Plasma HIV RNA and CD4+ T cell quantitation will be performed conventionally. HIV mRNA will be quantitated in LN and GALT using in-situ hybridization (ISH). Immunohistochemistry (IHC) will be performed to quantitate changes in CD4+ cell numbers over time in tissues from each respective ART regimen.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Efavirenz

Group Type ACTIVE_COMPARATOR

Efavirenz + Tenofovir DF/Emtricitabine

Intervention Type DRUG

600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks

Colonoscopy with biopsies

Intervention Type PROCEDURE

Day 0, Day 2, Day 7, Day 14, Week 52

Inguinal Lymph Node Excision

Intervention Type PROCEDURE

Day 0, Day 2, Day 7, Day 14, Week 52

Raltegravir

Group Type EXPERIMENTAL

Raltegravir + Tenofovir DF/Emtricitabine

Intervention Type DRUG

400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks

Colonoscopy with biopsies

Intervention Type PROCEDURE

Day 0, Day 2, Day 7, Day 14, Week 52

Inguinal Lymph Node Excision

Intervention Type PROCEDURE

Day 0, Day 2, Day 7, Day 14, Week 52

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Efavirenz + Tenofovir DF/Emtricitabine

600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks

Intervention Type DRUG

Raltegravir + Tenofovir DF/Emtricitabine

400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks

Intervention Type DRUG

Colonoscopy with biopsies

Day 0, Day 2, Day 7, Day 14, Week 52

Intervention Type PROCEDURE

Inguinal Lymph Node Excision

Day 0, Day 2, Day 7, Day 14, Week 52

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sustiva EFV Tenofovir Tenofovir Disoproxil Fumarate TDF Emtriva FTC Truvada Atripla Nucleoside Reverse Transcriptase Inhibitor NRTI Non-Nucleoside Reverse Transcriptase Inhibitor NNRTI Isentress MK-0518 Tenofovir Tenofovir Disoproxil Fumarate TDF Emtriva FTC Truvada Integrase Inhibitor Nucleoside Reverse Transcriptase Inhibitor NRTI Colonoscopy Biopsy Secondary Lymphatic Tissue Gastrointestinal GALT Peyers Patch Lamina Propria Secondary Lymphatic Tissue Inguinal Lymph Node LN Excision Biopsy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV positive (proven serologically at the time of screen, unless evidence for seroconversion)
* Evidence of recent (proven seroconversion within 4 months) or acute infection (HIV antibody negative, HIV RNA positive), or CD4 T Cells \> 350 in peripheral blood and plasma viral load \> 100,000 copies/ml
* Antiretroviral therapy naive (no prior history of antiretroviral therapy)
* Negative pregnancy test for eligible women of childbearing potential

Exclusion Criteria

* Contraindication to surgical and endoscopic procedures (as judged by the principal investigator)
* Psychiatric or psychological illness that would make adherence to protocol procedures unlikely
* Pregnancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No